Bibliography
- Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2004;2:CD003971
- Toombs JD, Kral L. Methadone treatment for pain states. Am Fam Physician 2005;71:1353-8
- Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005;19:13-24
- Ferrari A, Rosario Coccia CP, Bertolini A, et al. Methadone – metabolism, pharmacokinetics, and interactions. Pharmacol Res 2004;50:551-9
- Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002;5:127-38
- Berdine HJ, Nesbit SA. Equianalgesic dosing of opioids. J Pain Palliat Care Pharmacother 2006;20:79-84
- Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997;70:99-101
- Santiago-Palma J, Khojainova N, et al. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001;92:1919-25
- Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol 2003;1:216-20
- Zimmerman C, Seccareccia D, Booth CM, Cottrell W. Rotation to methadone after opioid dose escalation: how should individualization of dosing occur? J Pain Palliat Care Pharmacother 2005;19:25-31
- Yennurajalingam S, Braiteh F, Bruera E. Pain and terminal delirium research in the elderly. Clin Geriatr Med 2005;21:93-119
- Crettol S, Deglon JJ, Besson J, et al. ABCBI and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81
- Kharasch ED, Hoffer C, Whittington D, Scheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69
- Crettol S, Deglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604
- Brown R, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J 2004;80:654-9
- Wysowski DK: Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 2007;30:533-40
- Paulozzi LJ, Budnitz DS, Yongli X. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618-27
- Food and Drug Administration alert; 2006. Available at: URL: http://www.fda.gov/cder/drug/infopage/methadone/default/htm
- Dolophine® Hydrochloride (methadone hydrochloride tablets, USP), Roxane Laboratories, Inc. Columbus, Ohio, October 2006
- Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev 2007;11:35-46
- Walker JM, Farney RJ, Rhondeau SM. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;15:455-61
- Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lesions learned for pharmacology. Expert Opin Drug Saf 2007;6:289-303
- Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506
- Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG channel by S-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719-28